Victory Capital Management Inc. Sells 16,794 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Victory Capital Management Inc. lessened its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 20.2% during the third quarter, HoldingsChannel reports. The fund owned 66,279 shares of the biotechnology company’s stock after selling 16,794 shares during the quarter. Victory Capital Management Inc.’s holdings in Sarepta Therapeutics were worth $8,278,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in SRPT. Riggs Asset Managment Co. Inc. lifted its stake in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 75 shares in the last quarter. EP Wealth Advisors LLC lifted its holdings in Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after acquiring an additional 103 shares during the period. Cambridge Investment Research Advisors Inc. boosted its position in Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after purchasing an additional 120 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Sarepta Therapeutics by 16.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 155 shares during the last quarter. Finally, Innealta Capital LLC bought a new stake in Sarepta Therapeutics in the second quarter worth about $31,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SRPT. Evercore ISI decreased their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Needham & Company LLC restated a “buy” rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, November 7th. Finally, Guggenheim upped their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Sarepta Therapeutics Stock Down 0.3 %

SRPT stock opened at $110.50 on Friday. The stock has a market capitalization of $10.55 billion, a PE ratio of 88.40 and a beta of 0.81. The company has a fifty day moving average of $122.21 and a 200-day moving average of $131.71. Sarepta Therapeutics, Inc. has a one year low of $78.67 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.